CXCL9 and neoplasm: These results suggested that CXCL9 and αPD-L1 expressed by NPTyr-C9AP not only reinforced T-cell responses but also improved the tumor immune microenvironment, which jointly resulted in enhanced immunotherapy against melanoma.